{"protocolSection":{"identificationModule":{"nctId":"NCT02223273","orgStudyIdInfo":{"id":"BRIDGE-Stroke"},"organization":{"fullName":"Hospital do Coracao","class":"OTHER"},"briefTitle":"Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)","officialTitle":"A Cluster Randomized Trial to Evaluate the Increase in Usage of Evidence-based Practices for Stroke Treatment Using a Multifaceted Strategy","acronym":"BRIDGEStroke"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-02","type":"ACTUAL"},"completionDateStruct":{"date":"2018-06","type":"ACTUAL"},"studyFirstSubmitDate":"2014-08-19","studyFirstSubmitQcDate":"2014-08-20","studyFirstPostDateStruct":{"date":"2014-08-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-10-01","lastUpdatePostDateStruct":{"date":"2018-10-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hospital do Coracao","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Phase 1: An observational study ( registry) will be conducted with the objective of documenting the practice of stroke treatment in brazilian and latin american hospitals.\n\nPhase 2: A cluster randomized trial aiming to evaluate the effect of a multifaceted strategy to increase evidence based treatments usage for stroke patients. The hospitals will be randomized into two groups: the multifaceted strategy group and the usual care group.","detailedDescription":"Study Objective: The purpose of this study is to evaluate a multifaceted strategy to increase evidence based therapies for patients with acute ischemic stroke.\n\nStudy Population; Patients with suspected stroke or transient ischemic attack (TIA) with symptoms lasting up to 24h hours.\n\nQuality Improvement Multifaceted Intervention: The strategy includes a simulation based team training, case manager, check lists, reminders and educational material."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["stroke,","quality improvement"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"HEALTH_SERVICES_RESEARCH","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1624,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Multifaceted Strategy","type":"EXPERIMENTAL","description":"Multifaceted Intervention\n\n1. Simulation Based Team Training\n2. Case Manager\n3. Check lists\n4. Reminders\n5. Educational Materials","interventionNames":["Behavioral: Multifaceted Strategy"]},{"label":"Usual Care","type":"NO_INTERVENTION","description":"Hospital Standard Treatment"}],"interventions":[{"type":"BEHAVIORAL","name":"Multifaceted Strategy","description":"1. Simulation Based Team Training\n2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions\n3. Reminders -\n4. Check lists - decision support algorithm\n5. Distribution of educational materials: guidelines and recommendations for best practices","armGroupLabels":["Multifaceted Strategy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Frequency of Evidence Based Strategies","description":"For phase 1: Proportion of prescription of evidence-based strategies. in the first 48 hours and prior to discharge","timeFrame":"Discharge or 7 days after admission"},{"measure":"Composite Adherence Score","description":"Composite Adherence Score: defined as the sum of usage of evidence based therapies in the first 48 hours and at discharge among the patients' total eligible opportunities. For this purpose, patients with contraindications (which are specific for each endpoint) were excluded from the denominators. Evidence based therapies in the first 48 hours include: antithrombotics within 48 hours of admission, use of recombinant Plasminogen Activator (Rt-PA)in patients who arrive at the hospital within 3.5 hours of symptom onset and who are treated within 4.5 hours of symptom onset, dysphagia screening, pre-deep venous thrombosis prophylaxis, door to needle time \\< 60 minutes, dysphagia screening). Discharge Therapies include: antithrombotics, lipid lowering agents in patients with LDL 100 or not documented, anticoagulants for atrial fibrilation or flutter, assessment for rehabilitation and smoke cessation education","timeFrame":"Discharge or 7 days after admission"}],"secondaryOutcomes":[{"measure":"\"All or None\" Quality Measures","description":"Proportion of prescription of evidence-based strategies in the first 48 hours and at discharge \"All or none\" measures including the evidence based therapies in the first 48h: antithrombotics, use of recombinant Plasminogen Activator (Rt-PA)in patients who arrive at the hospital within 3.5 hours of symptom onset and who are treated within 4.5 hours of symptom onset, dysphagia screening, pre-deep venous thrombosis prophylaxis, door to needle time \\< 60 minutes, dysphagia screening). Discharge Therapies include: antithrombotics, lipid lowering agents in patients with LDL 100 or not documented, anticoagulants for atrial fibrilation or flutter, assessment for rehabilitation and smoke cessation education","timeFrame":"Discharge or 7 days after admission"},{"measure":"Additional Strategies","description":"Proportion of usage of the additional strategies: use of recombinant Plasminogen Activator (Rt-PA), anti-hypertensive agents, and door to needle time\\< 45 min)","timeFrame":"Discharge or 7 days after admission"},{"measure":"Total Mortality","description":"In hospital and 90 days mortality","timeFrame":"Discharge or 7 days after admission and 90 days"},{"measure":"Disability","description":"Degree of disability (measured by the Modified Rankin Scale) at discharge and in 90 days.","timeFrame":"90 days"},{"measure":"Stroke Recurrence","description":"Number of patients presenting a new stroke in 90 days","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Patient Eligibility Criteria\n\nInclusion Criteria:\n\n* Patients over 18 years old, diagnosed with ischemic stroke (including transient ischemic attack) with symptoms lasting up to 24 hours.\n\nExclusion Criteria:\n\n* Patients with signs of hemorrhagic stroke, expansive lesions, central nervous system infections, and those coming from institutions that did not provide institutional approval form signed by the patients' guardians.\n\nCluster Eligibility Criteria\n\nInclusion Criteria:\n\n* Hospitals with a emergency department, with available tomography, neurologist and alteplase\n\nExclusion Criteria:\n\n* Hospitals that don't provide Institutional Authorization Form","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Otavio Berwanger, MD, PhD","affiliation":"Hospital do Coração","role":"STUDY_CHAIR"},{"name":"M. Julia Machline Carrion, MD, MHS, PhD","affiliation":"Hospital do Coração","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Brazil","city":"São Paulo","zip":"04004-050","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}}]},"referencesModule":{"references":[{"pmid":"31058947","type":"DERIVED","citation":"Machline-Carrion MJ, Santucci EV, Damiani LP, Bahit MC, Malaga G, Pontes-Neto OM, Martins SCO, Zetola VF, Normilio-Silva K, Rodrigues de Freitas G, Gorgulho A, De Salles A, Pacheco da Silva BG, Santos JY, de Andrade Jesuino I, Bueno PRT, Cavalcanti AB, Guimaraes HP, Xian Y, Bettger JP, Lopes RD, Peterson ED, Berwanger O; BRIDGE-Stroke Investigators. Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack: A Cluster Randomized Clinical Trial. JAMA Neurol. 2019 Aug 1;76(8):932-941. doi: 10.1001/jamaneurol.2019.1012."},{"pmid":"30415083","type":"DERIVED","citation":"Machline-Carrion MJ, Santucci EV, Damiani LP, Bahit C, Malaga G, Pontes-Neto OM, Martins SCO, Zetola VF, Normilio-Silva K, de Freitas GR, Gorgulho A, De Salles A, da Silva BGP, Santos JY, de Andrade Jesuino I, Bueno PRT, Cavalcanti AB, Guimaraes HP, Xian Y, Bettger JP, Lopes RD, Peterson ED, Berwanger O. An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. Am Heart J. 2019 Jan;207:49-57. doi: 10.1016/j.ahj.2018.09.009. Epub 2018 Sep 30."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Acute Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}